GPP-INTER LLC has acquired Trypylot, a neurotechnology startup specializing in wearables for cognitive wellness, to position itself as a leader in the $410 billion cognitive wellness market.

Target Information

GPP-INTER LLC is a strategic development and investment firm specializing in the acquisition and transformation of high-potential technology assets. Its primary focus is on advancing innovations that can reshape industries. The firm's flagship initiative is the acquisition of Trypylot, an emerging startup based in New Zealand that specializes in neurotechnology wearables. Trypylot has developed a unique device that measures brain activity (EEG) and heart rate variability (HRV), empowering users to manage their mental energy more effectively than ever before.

By acquiring Trypylot, GPP-INTER aims to leverage this groundbreaking technology to establish a global platform dedicated to cognitive wellness, positioning itself as the industry leader in mental performance enhancement.

Industry Overview in New Zealand

The neurotechnology sector has been gaining traction globally, with increasing recognition of the importance of mental wellness and cognitive enhancement. In New Zealand, there is a growing in

View Source

Similar Deals

Medibank Better Medical

2026

Other Hospitals, Clinics & Primary Care Services Australia
Adicon Holdings Limited Crown Bioscience Inc.

2026

Other Biotechnology & Medical Research (NEC) China
佳辰资本 辐联科技

2025

Other Proprietary & Advanced Pharmaceuticals China
HammondCare Curtin property

2025

Other Residential & Long-Term Care Australia
Jack Burnett RAMM PHARMA Corp

2025

Other Proprietary & Advanced Pharmaceuticals Canada

GPP-INTER LLC

invested in

Trypylot

in 2025

in a Other deal

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert